Bio Roundup: So Long Celgene, RNAi’s Arrival, Pharma in 2020 & More
Xconomy
NOVEMBER 22, 2019
Bristol-Myers Squibb this week completed its acquisition of Celgene, a $74 billion deal that creates a pharmaceutical juggernaut. And all it took was the largest asset sale ever required by federal antitrust regulators.
Let's personalize your content